Iovance Biotherapeutics (IOVA) Amortization of Deferred Charges (2021 - 2026)

Iovance Biotherapeutics (IOVA) has reported Amortization of Deferred Charges for 6 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 34.63% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $10.4 million (down 5.63% YoY), while the FY2025 annual figure was $11.4 million, up 9.08% from the prior year.
• Amortization of Deferred Charges eased to $1.9 million in Q1 2026 per IOVA's latest filing, from $2.7 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $3.2 million in Q1 2022 and bottomed at $1.9 million in Q1 2026.
• Historically, Amortization of Deferred Charges has averaged $2.8 million across 5 years, with a median of $2.9 million in 2025.
• Annual changes were most pronounced in 2022 — Amortization of Deferred Charges jumped 32.43% — and 2026, when it tumbled 34.63%.
• Iovance Biotherapeutics' Amortization of Deferred Charges stood at $2.9 million in 2022, then dropped by 1.31% to $2.9 million in 2023, then increased by 10.89% to $3.2 million in 2024, then declined by 14.21% to $2.7 million in 2025, then tumbled by 30.93% to $1.9 million in 2026.
• Business Quant data shows IOVA's Amortization of Deferred Charges at $1.9 million in Q1 2026, $2.7 million in Q4 2025, and $2.9 million in Q3 2025.